References
- Shaw MJ, Fendrick AM, Kane RL, Adlis SA, Talley NJ. Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists. Am J Gastroenterol 2001; 96: 673–6
- Richtlijn Maagklachten. Kwaliteitsinstituut voor de Gezondheidszorg. Utrecht: CBO; 2004.
- Netzer P, Brabetz-Hofliger A, Brundler R, Flogerzi B, Husler J, Halter F. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. Aliment Pharmacol Ther 1998; 12: 337–42
- Andersen M, Schou JS. Are H2-receptor antagonists safe over the counter drugs?. Br Med J 1994; 309: 493–4
- Shi CW, Gralnek IM, Dulai GS, Towfigh A, Asch S. Consumer usage patterns of nonprescription histamine-2 receptor antagonists. Am J Gastroenterol 2004; 99: 606–10
- Gossel TA. Implications of the reclassification of drugs from prescription-only to over-the-counter status. Clin Ther 1991;13:200–215; discussion 199.
- Tasch RF, Goeree R, Henke CJ, O'Brien BJ. Switching the histamine H2-receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation. Pharmacoeconomics 1996; 9: 61–75
- Sihvo S, Hemminki E. Self-medication of dyspepsia: how appropriate is it?. Scand J Gastroenterol 1997; 32: 855–61
- Andrade SE, Gurwitz JH, Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Med Care 1999; 37: 424–30
- Myers RE, Ross E, Jepson C, Wolf T, Balchem A, Millner L, et al. Modeling adherence to colorectal cancer screening. Prev Med 1994; 23: 142–51
- Hunter MS, Liao KL. Intentions to use hormone replacement therapy in a community sample of 45-year-old women. Maturitas 1994; 20: 13–23
- Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000; 46: 464–7
- Panter SJ, O'Flanagan H, Bramble MG, Hungin AP. Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not affect outcome. Aliment Pharmacol Ther 2004; 19: 981–8
- Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006; 55: 1217–21
- van Vliet EP, Eijkemans MJ, Steyerberg EW, Kuipers EJ, Tilanus HW, van der Gaast A, et al. The role of socio-economic status in the decision making on diagnosis and treatment of oesophageal cancer in The Netherlands. Br J Cancer 2006; 95: 1180–5